McKesson to invest $1.4B in Option Care Health as CD&R-led buyout values company at ~$5.8B

McKesson (MCK) will invest $1.4B for a 49% stake in Option Care Health, as part of a $5.8B buyout led by CD&R. The deal values Option Care Health at $32.05 per share, a 37% premium over its Oct 5, 2026 closing price. The transaction is expected to close in H1 2027, subject to approvals.

Original reporting
Published Oct 6, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
McKesson to invest $1.4B in Option Care Health as CD&R-led buyout values company at ~$5.8B — source image
Decision brief

The 30-second read

$MCKBullishHigh
01

Why it matters

The transaction adds a sizable revenue stream for McKesson and provides a premium exit for Option Care shareholders, likely driving short-term price moves in both securities.

02

Market read

The deal is material for both companies and the broader healthcare sector, offering trading opportunities on announcement.

03

What to watch

Regulatory approval risk and potential debt load on McKesson may temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

The announcement follows a definitive agreement between McKesson and CD&R to acquire Option Care Health, marking a significant expansion for McKesson into home health services.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson announced a $1.4B minority investment for a ~49% stake in Option Care Health as part of a $5.8B acquisition.

Expected impact

potential upside as market prices in the strategic acquisition and minority stake.

Evidence & confidence

The deal adds a sizable asset and diversifies revenue, prompting investors to view MCK favorably.

$OPCHBullishHigh confidence
Context

Option Care Health is being acquired for $32.05 per share, a 37% premium, and will be taken private.

Expected impact

likely pressure upward to the $32.05 offer price as the transaction closes.

Evidence & confidence

A premium acquisition typically drives the target's stock up to the deal price.

Market effects

The deal highlights consolidation in the home health and pharmacy distribution sectors.

U.S. healthcare services market may see increased M&A activity.

Large-scale healthcare M&A can influence global investor sentiment toward health services stocks.

Counterpoint

If integration challenges arise, the premium paid could be viewed as overvaluation.

Key entities

  • McKesson Corp

    U.S. healthcare services and pharmaceutical distribution company.

  • Option Care Health

    Provider of home health and hospice services.

  • CD&R

    Private equity firm leading the acquisition.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.